• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Marpai Inc.

    4/26/23 5:18:18 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    SC 13G 1 mrai-sc13g_041723.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    Marpai, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

    571354109

    (CUSIP Number)

     

    April 17, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

    Page 2 of 9

     

    CUSIP No.    571354109    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,805,327 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,805,327 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,805,327 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.2%(1)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

    (1)Based on 29,012,464 shares, shares of Common Stock outstanding as set forth in the Issuer’s Form 424(b)(5) dated April 17, 2023, filed with the Securities and Exchange Commission on April 19, 2023.

     

      

    Page 3 of 9

     

     

    CUSIP No. 571354109    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,805,327 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,805,327 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,805,327 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.2%(1)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    _____________

    (1)Based on 29,012,464 shares, shares of Common Stock outstanding as set forth in the Issuer’s Form 424(b)(5) dated
    April 17, 2023, filed with the Securities and Exchange Commission on April 19, 2023.
     

      

    Page 4 of 9

     

    CUSIP No. 571354109    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    1,805,327 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,805,327 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,805,327 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.2%(1)

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

    ______________

    (1)Based on 29,012,464 shares, shares of Common Stock outstanding as set forth in the Issuer’s Form 424(b)(5) dated
    April 17, 2023, filed with the Securities and Exchange Commission on April 19, 2023.

      

    Page 5 of 9

     

     

     

    CUSIP No.   571354109    

     

    Item 1(a).   Name of Issuer:                                                         Marpai, Inc. (the “Issuer”)
         
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:   5701 East Hillsborough Avenue, Suite 1417

    Tampa, Florida 33610

         
         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.001 per share (“Common Stock”)
         
         
    Item 2(e).   CUSIP Number: 571354109
         
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

      

    Page 6 of 9

     

     

    CUSIP No. 571354109    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 29,012,464 shares of Common Stock outstanding as set forth in the Issuer’s Form 424(b)(5) dated April 17, 2023, filed with the Securities and Exchange Commission on April 19, 2023.

     

     

      

    Page 7 of 9

     

     

    CUSIP No . 571354109    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      Dated: April 25, 2023
       
     

    Altium Capital Management, LP

       
     

    By:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    CEO

       
     

    Altium Growth Fund, LP 

     

    By: Altium Growth GP, LLC

    Its: General Partner

     

      Signature: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member of Altium Growth GP, LLC
         
      Altium Growth GP, LLC
     
      By: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member

      

    Page 8 of 9

     

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1:

    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

      

    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Scrip Dallas was granted 100,000 shares (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:48:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSION

    Renews Aetna Signature Administrator Network Agreement and Enhances Cost Containment with Faircost Optimizer TAMPA, Fla., Dec. 1, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced significant positive momentum heading into the new year, highlighted by a better-than-expected sales cycle for 2026 and the renewal of its critical network access agreement with Aetna. The Company reports a robust sales cycle, securing a volume of new clients for January 1, 2026, that surpasses internal expectations, reinforcing its path to scalable growt

    12/1/25 4:04:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    SEC Filings

    View All

    Marpai Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement

    8-K - Marpai, Inc. (0001844392) (Filer)

    1/23/26 4:02:33 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    1/9/26 2:43:57 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    12/22/25 7:14:49 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

    STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

    1/22/25 5:00:00 PM ET
    $HIT
    $MRAI
    Specialty Insurers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care